BC Week In Review | Dec 1, 2017
Financial News

ProQR Therapeutics raises $20M

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $20 million on Nov. 14 through the sale of 5 million shares in a public offering and 1.4 million shares in a concurrent registered direct offering, each at a price...
BioCentury | May 16, 2016

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Sep 21, 2015
Clinical News

QR-010: Proof-of-concept trial started

ProQR began the open-label, international, proof-of-concept PQ-010-002 trial to evaluate thrice-weekly QR-010 applied directly to the nasal mucosa for 4 weeks in >=16 patients with 1-2 copies of the delta F508 CFTR mutation. ProQR Therapeutics...
BC Week In Review | Aug 3, 2015
Clinical News

QR-010: Phase Ib started

ProQR began the double-blind, placebo-controlled, international Phase Ib PQ-010-001 trial to evaluate single and multiple ascending doses of inhaled QR-010 in 64 patients who are homozygous for the delta F508 mutation in the CFTR gene....
BioCentury | Jul 13, 2015

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders largely...
BC Extra | Sep 19, 2014
Top Story

ProQR raises $97.5M in bumped up IPO

ProQR Therapeutics N.V. (NASDAQ:PRQR) jumped $1.73 (13%) to $14.73 in its first day of trading Thursday after raising $97.5 million through the sale of 7.5 million shares at $13 in an IPO. The IPO price...
BioCentury | Sep 15, 2014

ProQR tests IPO threshold

While investors typically see preclinical companies as being too early for the public markets, a few examples from the current IPO window hint that Dutch cystic fibrosis play ProQR Therapeutics B.V. could be another exception...
BC Extra | Sep 9, 2014
Financial News

ProQR sets IPO range

ProQR Therapeutics B.V. (Leiden, the Netherlands) set terms for its IPO on NASDAQ. The company plans to sell 6.3 million shares at $11-$13. At the $12 midpoint, the company would raise $75 million and be...
Items per page:
1 - 9 of 9